Dr Maria Leandro

Dr Maria LeandroTel: 020 3447 9487
Fax: 020 3447 9238
Email: uclh.rheumatology@nhs.net

Location:
University College Hospital

Specialities:
Rheumatology

Professional background

Maria Leandro is consultant rheumatologist at UCL Hospitals and is an honorary senior lecturer at University College London. Maria studied medicine at Universidade Nova de Lisboa and trained as a rheumatologist at Hospital de Santa Maria in Lisbon, Portugal. She was previously a research fellow at University College London and awarded a PhD for her work on the mechanisms of disease relapse in rheumatoid arthritis following B cell depletion therapy. Maria's key interests are in inflammatory arthritis, rheumatoid arthritis, B cell directed therapies in autoimmune diseases and role of B cells in the pathogenesis of autoimmune diseases.

Research interests

Inflammatory arthritis, rheumatoid arthritis and B cell directed therapies in autoimmune rheumatic diseases.

Publications

Cambridge G, Moura RA, Santos T, Khawaja AA, Polido-Pereira J, Canhao H, Leandro MJ, Fonseca JE. Expression of the inherently autoreactive idiotope 9G4 on autoantibodies to citrullinated peptides and on rheumatoid factors in patients with early and established rheumatoid arthritis. PLoS One 2014 Sep 15;9(9):e107513

Reddi V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy? Future Medicine in press

Leandro MJ. Historic outline of the development of drugs targeting B cells. In “Drugs targeting B-cells in autoimmune diseases”. Edited by Xavier Bosch, Manuel Ramos-Casals, Munther A Khamashta, Springer, 2014.

Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, De La Torre I, Dickson MC, Leandro MJ, Edwards JC. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun 2014 May;50:67-76.

Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus – report of 17 cases and review of the literature. Lupus 2013 Aug;22(9):932-9.

Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Research & Therapy 2013;15 Suppl 1:S3.

Reddy V, Croca S, Gerona D, De La Torre I, Isenberg D, McDonald V, Leandro M, Cambridge G. Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology 2013;52:951-2.

De La Torre I, Leandro MJ, Gerona D, Valor L, Carreno L, Cambridge G. Impact of non-fixed versus 6 month fixed retreatment schedules on serum immunoglobulins following rituximab in patients with rheumatoid arthritis. Journal of Clinical & Cellular Immunology 2013, in press.

Elena Becerra, Geraldine Cambridge, Inmaculada de la Torre, Maria J Leandro.  Long-term safety of rituximab in patients with rheumatoid arthritis. International Journal of Clinical Rheumatology 2012; 7(4): 383-390.

Jonathan C W Edwards and Maria J Leandro. Rheumatoid arthritis. In “Understanding Medical Research. The studies that shaped medicine. Edited by John A Goodfellow, Wiley-Blackwell, 2012.

De La Torre I, Leandro MJ, Edwards JC, Cambridge G. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin Exp Rheumatol 2012; 30(4): 554-560.

De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) 2012; 51(5): 833-40.

B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy.
de la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G.
Ann Rheum Dis. 2010 Dec;69(12):2181-8.

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis.
Leandro MJ.
Arthritis Res Ther. 2009;11(5):128. Review.

Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.
Leandro MJ, de la Torre I.
Clin Exp Immunol. 2009 Aug;157(2):191-7. Review.

Rituximab in non-haematological disorders of adults and its mode of action.
McDonald V, Leandro M.
Br J Haematol. 2009 Aug;146(3):233-46. Review.

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.
Arthritis Rheum. 2009 Apr 15;61(4):482-7.

Lymphoid follicles in joints: what do they mean?
Edwards JC, Leandro MJ.
Arthritis Rheum. 2008 Jun;58(6):1563-5.

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.
Ann Rheum Dis. 2008 Jul;67(7):1011-6.

B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres.
Ioannou Y, Lambrianides A, Cambridge G, Leandro MJ, Edwards JC, Isenberg DA.
Ann Rheum Dis. 2008 Mar;67(3):425-6.

Repeated B-cell depletion in clinical practice.
Edwards JC, Cambridge G, Leandro MJ.
Rheumatology (Oxford). 2007 Sep;46(9):1509.

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.
Ann Rheum Dis. 2007 Sep;66(9):1259-62.

B cell depletion in systemic lupus erythematosus.
Leandro MJ, Ehrenstein MR.
Clin Med. 2007 Jan-Feb;7(1):57-9. Review.

Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C, Leandro MJ, Cambridge G, Edwards JC.
Rheumatology (Oxford). 2007 Apr;46(4):626-30.

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC.
Arthritis Rheum. 2006 Nov;54(11):3612-22.

B cell depletion therapy in rheumatic disease.
Edwards JC, Cambridge G, Leandro MJ.
Best Pract Res Clin Rheumatol. 2006 Oct;20(5):915-28. Review.

Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.
Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC.
Rheumatology (Oxford). 2007 Jan;46(1):29-36.

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC.
Arthritis Rheum. 2006 Mar;54(3):723-32.

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC.
Arthritis Rheum. 2006 Feb;54(2):613-20.

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus.
Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA.
Ann Rheum Dis. 2006 Jul;65(7):942-5.

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA.
Rheumatology (Oxford). 2005 Dec;44(12):1542-5.

B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
Edwards JC, Leandro MJ, Cambridge G.
Curr Dir Autoimmun. 2005;8:175-92.

Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?
Gorman C, Leandro M, Isenberg D.
Lupus. 2004;13(5):312-6. Review.

B cell depletion in autoimmune disease.
Gorman C, Leandro M, Isenberg D.
Arthritis Res Ther. 2003;5 Suppl 4:S17-21. Review.

B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.
Edwards JC, Leandro MJ, Cambridge G.
Rheum Dis Clin North Am. 2004 May;30(2):393-403, viii. Review.

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD.
Arthritis Rheum. 2003 Aug;48(8):2146-54.

An open study of B lymphocyte depletion in systemic lupus erythematosus.
Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA.
Arthritis Rheum. 2002 Oct;46(10):2673-7.

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
Leandro MJ, Edwards JC, Cambridge G.
Ann Rheum Dis. 2002 Oct;61(10):883-8.

B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders.
Edwards JC, Leandro MJ, Cambridge G.
Biochem Soc Trans. 2002 Aug;30(4):824-8. Review.

 

GMC/GDC number: 4664778